Invited commentary on pearl and principal stratification

International Journal of Biostatistics

Volumn 7, Issue 1, 2011, Pages

  Prentice, Ross ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Causal inference; principal stratification; women's health initiative (WHI)

Indexed keywords

CONJUGATED ESTROGEN; MEDROXYPROGESTERONE ACETATE;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; FEMALE; HORMONAL THERAPY; HUMAN; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; POSTMENOPAUSE; PRINCIPAL STRATUM FRAMEWORK; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RELIABILITY; STRATIFIED SAMPLE; WOMEN'S HEALTH; EPIDEMIOLOGY; METHODOLOGY; NOTE; STATISTICAL MODEL;

CAUSALITY; HUMANS; MODELS, STATISTICAL; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESEARCH DESIGN;

EID: 80052498129     PISSN: None     EISSN: 15574679     Source Type: Journal    
DOI: 10.2202/1557-4679.1359     Document Type: Article

References (25)

1. Chlebowski RT, Anderson GL, Gass M, et al. Estrogen plus progestin and breast cancer incidence and mortality in postmenopausal women. JAMA 2010;304(15):1684-1692.
2. Chlebowski RT, Kuller LH, Prentice RL, et al; WHI Investigators. Breast cancer after use of estrogen plus progestin in postmenopausal women. N Engl J Med 2009;360(6):573-587.
3. Cox DR. Comment on 'Causal Inference Without Counterfactuals'. J Am Stat Assoc 2000;95(450):424-425.
4. Dawid AP. Causal inference without counterfactuals. J Am Statist Assoc 2000;95(450):407-424.
5. Frangakis CE and Rubin DB. Principal stratification in causal inference. Biometrics 2002;58:21-29. (Pubitemid 34194484)
6. Imbens GW and Rubin DB. Bayesian inference for causal effects in randomized experiments with noncompliance. Ann Statist 1997;25(1):305-327.
7. Kooperberg C, Cushman M, Hsia J, et al. Can biomarkers identify women at increased stroke risk? The Women's Health Initiative Hormone Trials. PLoS Clin Trials 2007;2(6):e28.
8. Li Y, Taylor JMG, Elliott MR. Causal assessment of surrogacy in a meta-analysis of colorectal cancer trials. Biostatistics 2011;12(3):478-492.
9. Neuhouser ML, Tinker L, Shaw PA, et al. Use of recovery biomarkers to calibrate nutrient consumption self-reports in the Women's Health Initiative. Am J Epidemiol 2008;167(10):1247-1259. (Pubitemid 351670635)
10. Pearl, Judea (2011) "Principal Stratification-a Goal or a Tool?," The International Journal of Biostatistics: Vol. 7: Iss. 1, Article 20.
11. Pitteri SJ, Hanash SM, Aragaki A, et al. Postmenopausal estrogen and progestin effects on the serum proteome. Genome Medicine 2009;1(12):121.1-121. 14.
12. Prentice RL. Surrogate endpoints in clinical trials: discussion, definition and operational criteria. Stat Med 1989;8:431-440. (Pubitemid 19105891)
13. Prentice RL. Surrogate and mediating endpoints: current status and future directions (editorial). J Natl Cancer Inst 2009;101:216-217.
14. Prentice RL and Zhao S. On the use of biomarkers to elucidate clinical trial results: examples from the Women's Health Initiative. Invited paper for Proceedings of the 4th Seattle Biostatistics Symposium: Clinical Trials, 2011.
15. Prentice RL, Manson JE, Langer RD, et al. Benefits and risks of postmenopausal hormone therapy when it is initiated soon after menopause. Am J Epidemiol 2009a;170(1):12-23.
16. Prentice RL, Huang Y, Hinds DA, et al. Variation in the FGFR2 gene and the effects of postmenopausal hormone therapy on invasive breast cancer. Cancer Epidemiol Biomarker Prev 2009b;18(11):3079-3085.
17. Prentice RL, Paczesny SJ, Aragaki A, et al. Novel proteins associated with risk for coronary heart disease or stroke among postmenopausal women identified by in-depth plasma proteome profiling. Genome Med 2010;2(7):48-60.
18. Psaty BM and Prentice RL. Minimizing bias in randomized trials. The importance of blinding. JAMA 2010;304(7):793-794.
19. Ravdin PM, Cronin KA, Howlader N, et al. The decrease in breast-cancer incidence in 2003 in the United States. N Engl J Med 2007;356(16):1670-1674. (Pubitemid 46631679)
20. Robins, JM. "Marginal Structural Models Versus Structural Nested Models as Tools for Causal Inference," in Statistical Models in Epidemiology: The Environment and Clinical Trials, eds. M. E. Halloran and D. Berry, New York: Springer-Verlag,1999, pp. 95-134.
21. Rosenbaum P and Rubin DB. The central role of the propensity score in observational studies for causal effects. Biometrika 1983;70:41-55.
22. Rossouw JE, Cushman M, Greenland P, et al. Inflammatory, lipid, thrombotic, and genetic markers of coronary heart disease risk in the Women's Health Initiative trials of hormone therapy. Arch Intern Med 2008;168(20):2245-2253.
23. Sjolander A, Vansteelandt S, Humphreys K. A principal stratification approach to assess the differences in prognosis between cancers caused by hormone replacement therapy and by other factors. Int J Biostat 2010;6(1):Article 20.
24. Vansteelandt S and Keiding N. Invited commentary: G-computation-lost in translation? Am J Epidemiol 2011;173(7):739-742. Epub 2011 Mar 16.
25. Writing Group for the Women's Health Initiative (Rossouw JE, Anderson G, Prentice RL, et al) Risks and benefits of estrogen plus progestin in healthy postmenopausal women. JAMA 2002; 288:321-333.